论文部分内容阅读
目的为探讨D-二聚体(D-dimer)变化与原发性肝癌临床分期关系.方法:采用酶联免疫吸附反应检测了85例不同临床分期肝癌患者血浆D-二聚体含量.结果:各临床分期肝癌患者D-二聚体均显著高于对照组(P<0.01),且不同临床分期肝癌患者之间,D-二聚体聚体含重相差非常显著P<0.01).随肝癌患者病情加重,转移发生,D-二聚体呈递增趋势.在Ⅲ期病人,D-二聚体100%升高.结论:D-二聚体不仅可以反映患者呈现的不同程度的纤溶亢进,而且可以作为肝癌患者预后判断的指标.
Objective To investigate the relationship between the changes of D-dimer and the clinical stage of primary liver cancer. Methods: The plasma D-dimer content in 85 patients with different clinical stages of liver cancer was detected by enzyme-linked immunosorbent assay. Results: The D-dimer levels of liver cancer patients in each clinical stage were significantly higher than those in the control group (P<0.01), and the difference in weight of D-dimer aggregates between patients with different clinical stages was very significant (P<0.01). The patient’s condition aggravates and metastasis occurs. D-dimer increases. In stage III patients, D-dimer increases by 100%. Conclusion: D-dimer can not only reflect the degree of fibrinolytic activity presented by patients. , And can be used as an indicator of prognosis of liver cancer patients.